Clarus Therapeutics Expects To Initiate In H2 Of 2022 A Phase 2 Clinical Trial To Provide Treatment Of Inflammatory Breast Disease, Expects To Initiate In H2 Of 2022, A Phase 4 Clinical Trial To Provide T Therapy For Female-To-Male Transgender Individuals